Methods for treating diseases related to the wnt pathway
| DWPI Title: Treating viral infection e.g. hantavirus and California encephalitis virus, comprises administering both tankyrase inhibitor and transcriptional activity inhibitor by inhibiting Wnt/beta-catenin signaling after cellular entry by virus |
| Abstract: The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway. |
| Use: The method is useful for: treating a viral infection in a subject comprises the infection from a segmented RNA virus, infection from a rift valley fever virus, hantavirus, California encephalitis virus, Crimean-Congo hemorrhagic fever virus, La crosse virus, an infection from a Bunyavirus, infection from an arthropod-borne virus or infection from a virus of Phlebovirus genus and the subject is a human subject (all claimed); conducting a genome-wide screening to determine at least one gene resulting in a reduced disease state and identifying the gene(s) as being involved in the Wnt signaling pathway; and identifying dysregulation of a host's cellular regulatory pathway upon being exposed to a causative agent for a disease. Test details are described but no results given. |
| Novelty: Treating (M1) viral infection in a subject, comprises (a) administering both tankyrase inhibitor and transcriptional activity inhibitor to treat the viral infection by inhibiting Wnt/β -catenin signaling after cellular entry by a virus, where the tankyrase inhibitor and the transcriptional activity inhibitor are administered after exposure to the virus causing the viral infection and administered at least one hour post infection, the viral infection comprises an infection from a Bunyavirus. The tankyrase inhibitor comprises e.g. N-[4-[[4-(4-25 methoxyphenyl)oxan-4-yl]methylcarbamoyl]phenyl]furan-2-carboxamide and 2-[4-(trifluoromethyl)phenyl]-1,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one or its salt. The transcriptional activity inhibitor comprises e.g. Wnt pathway inhibitor XII ((E)-4-(2,6-difluorostyryl)-N,N-dimethylanilin) and iCRT-14 or (5Z)-5-[(2,5-dimethyl-1-pyridin-3-ylpyrrol-3-yl)methylidene]-3-phenyl-1,3-thiazolidine-2,4-dione or its salt. |
| Filed: 7/7/2016 |
| Application Number: US15204804A |
| Tech ID: SD 13466.1 |
| This invention was made with Government support under Contract No. DE-NA0003525 awarded by the United States Department of Energy/National Nuclear Security Administration. The Government has certain rights in the invention. |
| Data from Derwent World Patents Index, provided by Clarivate All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license. |